Cisatracurium

Pharmacologic Category

Neuromuscular Blocker Agent, Nondepolarizing

Dosing: Adult

Note: Dose to effect; doses must be individualized due to interpatient variability. Ensure adequate pain control and sedation prior to and during administration of neuromuscular blockade to achieve deep sedation (SCCM [Murray 2016]).

Intensive care unit paralysis (eg, use for up to 48 hours in patients with early ARDS with PaO2/FiO2 <150, to facilitate mechanical ventilation, or for shivering from therapeutic hypothermia) (SCCM [Murray 2016]):

0.1 to 0.2 mg/kg loading dose followed immediately by an infusion of 1 to 3 mcg/kg/minute (0.06 to 0.18 mg/kg/hour); adjust rate accordingly (Greenberg 2013) or in patients with acute respiratory distress syndrome to prevent ventilator asynchrony (off-label use), may administer a non-weight based dosing regimen of 15 mg (loading dose) followed immediately by 37.5 mg/hour for 48 hours; may administer 20 mg rapid boluses during infusion based on clinical parameters (eg, end-inspiratory plateau pressure remains >32 cm H2O) (Papazian 2010; SCCM [Murray 2016]).

Manufacturer's labeling: Dosing in the prescribing information may not reflect current clinical practice. 0.15 to 0.2 mg/kg loading dose; at initial signs of recovery from bolus dose, begin the infusion at a dose of 3 mcg/kg/minute (0.18 mg/kg/hour) and adjust rate accordingly; dosage ranges of 0.5 to 10 mcg/kg/minute (0.03 to 0.6 mg/kg/hour) have been reported.

Neuromuscular blockade for endotracheal intubation, surgery, or mechanical ventilation (as adjunct to general anesthesia): IV:

Operating room administration:

Intubating dose: 0.15 to 0.2 mg/kg bolus as components of propofol or thiopental/nitrous oxide/oxygen induction-intubation technique; doses up to 0.4 mg/kg have been administered. Note: May produce generally good or excellent conditions for tracheal intubation in 1.5 to 2 minutes with clinically effective duration of action during propofol anesthesia of 55 to 61 minutes. In patients with neuromuscular diseases (eg, myasthenia gravis, myasthenic syndrome, carcinomatosis), maximum initial bolus dose is 0.02 mg/kg. Initial dose after succinylcholine for intubation: 0.1 mg/kg

Maintenance dose:

Intermittent bolus dosing: 0.03 mg/kg 40 to 50 minutes (after initial dose of 0.15 mg/kg) or 50 to 60 minutes (after an initial dose of 0.2 mg/kg), then as needed based on clinical response.

Continuous infusion: After an initial bolus, a diluted solution can be given by continuous infusion for maintenance of neuromuscular blockade during extended surgery; adjust the rate of administration according to the patient's response as determined by peripheral nerve stimulation. An initial infusion rate of 3 mcg/kg/minute (0.18 mg/kg/hour) may be required to rapidly counteract the spontaneous recovery of neuromuscular function; thereafter, a rate of 1 to 2 mcg/kg/minute (0.06 to 0.12 mg/kg/hour) should provide 89% to 99% neuromuscular blockade in most patients. Consider reduction of the infusion rate by 30% to 40% when administering during stable isoflurane, enflurane, sevoflurane, or desflurane anesthesia. Spontaneous recovery from neuromuscular blockade following discontinuation of infusion of cisatracurium may be expected to proceed at a rate comparable to that following single bolus administration.

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Refer to adult dosing. Consider extending the interval between administration of cisatracurium and intubation attempt by at least 1 minute to achieve adequate intubation conditions (time to maximum neuromuscular blockade is ~1 minute slower in elderly patients).

Dosing: Renal Impairment: Adult

There are no specific dosage adjustments provided in the manufacturer's labeling. The half-life values of the metabolites are longer in patients with renal failure and concentrations may be higher after long-term administration. In patients with ESRD, consider extending the interval between the administration of cisatracurium and intubation attempt by at least 1 minute to achieve adequate intubation conditions (time to maximum neuromuscular blockade is ~1 minute slower in patients with ESRD).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling. The half-life values of the metabolites are longer in patients with hepatic disease and concentrations may be higher after long-term administration.

Dosing: Obesity: Adult

Ideal body weight or an adjusted body weight (ie, between IBW and total body weight [TBW]) is recommended when calculating dose for obese patients (SCCM [Murray 2016]).

Dosing: Pediatric

Note: Dosing in obese patients should be calculated using ideal body weight (Playfor 2007):

Neuromuscular blockade: IV (not to be used IM):

Intermittent dosing:

Infants and Children <2 years: 0.15 mg/kg over 5 to 10 seconds

Children ≥2 years and Adolescents: 0.1 to 0.15 mg/kg over 5 to 10 seconds (Martin 1999; Playfor 2007)

Continuous IV infusion: Infants, Children, and Adolescents: 1 to 4 mcg/kg/minute (0.06 to 0.24 mg/kg/hour); 3.9 ± 1.3 mcg/kg/minute (0.23 ± 0.08 mg/kg/hour) was the mean infusion rate needed to maintain neuromuscular blockade in 19 children (ages 3 months to 16 years) (Burmester 2005; Martin 1999; Playfor 2007); higher doses have been reported with prolonged infusions (Tobias 1997)

Dosing: Renal Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling. Slower times to onset of complete neuromuscular block were observed in renal dysfunction patients; extending the interval between the administration of cisatracurium and intubation attempt may be required to achieve adequate intubation conditions.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling. The time to onset of action was ~1 minute faster in patients with end-stage liver disease, but was not associated with clinically significant changes in recovery time.

Calculations

• Cisatracurium

Use: Labeled Indications

Neuromuscular blockade for endotracheal intubation, surgery, or mechanical ventilation: As an adjunct to general anesthesia, to facilitate endotracheal intubation, and to relax skeletal muscles during surgery or mechanical ventilation in adequately sedated ICU patients

Note: Neuromuscular blockade does not provide pain control, sedation, or amnestic effects. Appropriate analgesic and sedative mediations should be used before and during administration of neuromuscular blockade to achieve deep sedation.

* See Uses in AHFS Essentials for additional information.

Use: Off-Label: Adult

Acute respiratory distress syndromeLevel of Evidence [B, G]

Data from a multicenter, placebo-controlled randomized trial in mechanically ventilated patients with moderate/severe acute respiratory distress syndrome (ARDS) and PaO2/FiO2 ≤150 mmHg for less than 48 hours supports the use of cisatracurium for a duration of 48 hours to improve 90-day survival in this population. However, subgroup analysis found the greatest benefit when PaO2/FiO2 ≤120 mmHg Ref. Some experts recommend that neuromuscular blockers be considered for short-term use (up to 48 hours) only in patients with ARDS and severe gas exchange abnormalities (PaO2/FiO2 ≤120 mmHg) Ref.

Based on the Society for Critical Care Medicine Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient, a neuromuscular blocker may be considered for short-term use (up to 48 hours) via continuous infusion during the early course of acute respiratory distress syndrome (ARDS) in adults with PaO2/FiO2 <150 mmHg Ref.

Shivering due to therapeutic hypothermia following cardiac arrestLevel of Evidence [G]

Based on the Society for Critical Care Medicine Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient, a neuromuscular blocker may be used to manage overt shivering in therapeutic hypothermia following cardiac arrest.

Level of Evidence Definitions

Level of Evidence Scale

Clinical Practice Guidelines

Critical Care:

ACCM/SCCM/ASHP, “Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient,” January 2002

SCCM, “Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient,” 2016

“Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016,” March 2017

Usual Infusion Concentrations: Adult

IV infusion: 100 mg in 250 mL (total volume) (concentration: 400 mcg/mL) of D5W or NS

Administration: IV

Administer IV only; do not administer IM (excessive tissue irritation). Administer undiluted as a bolus injection over 5 to 10 seconds. Continuous administration requires the use of an infusion pump.

Administration: Pediatric

Parenteral: Not for IM injection due to tissue irritation

Rapid IV injection: Administer undiluted over 5 to 10 seconds

Continuous IV infusion: Further dilute in D5W or NS and administer via infusion pump

Storage/Stability

Refrigerate intact vials at 2°C to 8°C (36°F to 46°F). Use vials within 21 days upon removal from the refrigerator to room temperature of 25°C (77°F). Per the manufacturer, dilutions of 0.1 mg/mL in 0.9% sodium chloride (NS), dextrose 5% in water (D5W), or D5NS are stable for up to 24 hours at room temperature or under refrigeration; dilutions of 0.1-0.2 mg/mL in D5LR are stable for up to 24 hours in the refrigerator. Additional stability data: Dilutions of 0.1, 2, and 5 mg/mL in D5W or NS are stable in the refrigerator for up to 30 days; at room temperature (23°C), dilutions of 0.1 and 2 mg/mL began exhibiting substantial drug loss between 7-14 days; dilutions of 5 mg/mL in D5W or NS are stable for up to 30 days at room temperature (23°C) (Xu, 1998). Usual concentration: 0.1-0.4 mg/mL.

Preparation for Administration: Pediatric

Parenteral: Continuous IV infusion: Further dilute in D5W or NS to a final concentration of 0.1 to 0.4 mg/mL

Compatibility

See Trissel’s IV Compatibility Database

Open Trissel's IV Compatibility

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to calm muscles during surgery.

• It is used to calm muscles while on a breathing machine.

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Seizures

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Safety Issues

Sound-alike/look-alike issues:

High alert medication:

Other safety concerns:

Contraindications

Hypersensitivity to cisatracurium or any component of the formulation; use of the 10 mL multiple-dose vials in neonates <1 month of age and low birth-weight infants (formulation contains benzyl alcohol)

Documentation of allergenic cross-reactivity for neuromuscular blockers is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.

Warnings/Precautions

Concern related to adverse effects:

• Anaphylaxis: Severe anaphylactic reactions have been reported (some life-threatening and fatal). Appropriate emergency treatment (including epinephrine 1 mg/mL) should be immediately available during use. Use caution in patients with previous anaphylactic reactions to other neuromuscular blocking agents.

• Bradycardia: May be more common with cisatracurium than with other neuromuscular-blocking agents since it has no clinically-significant effects on heart rate to counteract the bradycardia produced by anesthetics.

• Residual paralysis: Has been reported. Patients with neuromuscular diseases (eg, myasthenia gravis, myasthenic syndrome) and carcinomatosis may be at increased risk; a lower maximum initial bolus dose is recommended in these patients. Reversal agents may be considered, especially in cases where residual paralysis is more likely to occur. To prevent complications from residual paralysis, extubation is recommended only after the patient has sufficiently recovered from neuromuscular blockade.

Disease-related concerns:

• Burn injury: Resistance may occur in burn patients (≥20% of total body surface area), usually several days after the injury, and may persist for several months after wound healing (Han 2009).

• Conditions that may antagonize neuromuscular blockade (decreased paralysis): Respiratory alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, and muscle trauma may result in antagonism of neuromuscular blockade (ACCM/SCCM/ASHP [Murray 2002]; Greenberg 2013; Miller 2010; Naguib 2002).

• Conditions that may potentiate neuromuscular blockade (increased paralysis): Electrolyte abnormalities (eg, severe hypocalcemia, severe hypokalemia, hypermagnesemia), neuromuscular diseases, metabolic acidosis, respiratory acidosis, Eaton-Lambert syndrome and myasthenia gravis may result in potentiation of neuromuscular blockade (Greenberg 2013; Miller 2010; Naguib 2002).

• Therapeutic hypothermia: Hypothermia may slow Hoffmann elimination thereby prolonging the duration of paralysis (Greenberg 2013).

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Special populations:

• Elderly: Use with caution in the elderly, effects and duration are more variable.

• Immobilized patients: Resistance may occur in patients who are immobilized.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.

Other warnings/precautions:

• Appropriate use: Maintenance of an adequate airway and respiratory support is critical. All patients should receive eye care including liberal use of lubricating drops, gel, or ointment and eyelids should remain closed during continuous neuromuscular blockade to protect against damage to the cornea (ulceration and drying).

• Experienced personnel: Should be administered by adequately trained individuals familiar with its use.

• Risk of medication errors: Accidental administration may be fatal. Confirm proper selection of intended product, store vial so the cap and ferrule are intact and the possibility of selecting the wrong product is minimized, and ensure that the intended dose is clearly labeled and communicated, when applicable.

* See Cautions in AHFS Essentials for additional information.

Pregnancy Considerations

Adverse events have not been observed in animal reproduction studies.

Breast-Feeding Considerations

It is not known if cisatracurium is present in breast milk. The manufacturer recommends that caution be exercised when administering cisatracurium to breastfeeding women.

Adverse Reactions

Effects are minimal and transient.

<1%, postmarketing, and/or case reports: Bradycardia, bronchospasm, flushing, hypotension, muscle calcification (prolonged use), myopathy (acute quadriplegic syndrome; prolonged use), pruritus, skin rash

* See Cautions in AHFS Essentials for additional information.

Allergy and Idiosyncratic Reactions

• Neuromuscular-Blocking Agent Allergy

Metabolism/Transport Effects

None known.

Drug Interactions Open Interactions

Acetylcholinesterase Inhibitors: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Aminoglycosides: May enhance the therapeutic effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Bacitracin (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Botulinum Toxin-Containing Products: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Bromperidol: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Calcium Channel Blockers: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Capreomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

CarBAMazepine: May decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Cardiac Glycosides: Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides. Risk C: Monitor therapy

Clindamycin (Topical): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Colistimethate: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk D: Consider therapy modification

Corticosteroids (Systemic): Neuromuscular-Blocking Agents (Nondepolarizing) may enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. Risk D: Consider therapy modification

CycloSPORINE (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Fosphenytoin-Phenytoin: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Inhalational Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Management: When initiating a non-depolarizing neuromuscular blocking agent (NMBA) in a patient receiving an inhalational anesthetic, initial NMBA doses should be reduced 15% to 25% and doses of continuous infusions should be reduced 30% to 60%. Risk D: Consider therapy modification

Ketorolac (Nasal): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination. Risk C: Monitor therapy

Ketorolac (Systemic): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination. Risk C: Monitor therapy

Lincosamide Antibiotics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Lithium: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Local Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Exceptions: Benzocaine; Benzydamine; Cocaine (Topical); Dibucaine; Dyclonine; Ethyl Chloride; Hexylresorcinol; Lidocaine (Ophthalmic); Lidocaine (Topical); Pramoxine; Proparacaine; Tetracaine (Ophthalmic); Tetracaine (Topical). Risk C: Monitor therapy

Loop Diuretics: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Magnesium Salts: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Minocycline (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Pholcodine: May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents. Specifically, anaphylaxis has been reported. Risk C: Monitor therapy

Polymyxin B: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk D: Consider therapy modification

Procainamide: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

QuiNIDine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

QuiNINE: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk X: Avoid combination

Spironolactone: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Tetracyclines: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Thiazide and Thiazide-Like Diuretics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Trimebutine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Vancomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Monitoring Parameters

Vital signs (heart rate, blood pressure, respiratory rate); degree of muscle paralysis (eg, presence of spontaneous movement, ventilator asynchrony, shivering, and use of a peripheral nerve stimulator with train of four monitoring along with clinical assessments)

In the ICU setting, prolonged paralysis and generalized myopathy, following discontinuation of agent, may be minimized by appropriately monitoring degree of blockade.

Advanced Practitioners Physical Assessment/Monitoring

Obtain heart rate, blood pressure, respiratory rate, and degree of muscle relaxation continuously during therapy. Ventilatory support must be instituted and maintained until adequate respiratory muscle function and/or airway protection are assured. Monitor for prolonged paralysis and generalized myopathy in patients on long-term therapy.

Nursing Physical Assessment/Monitoring

Ventilatory support must be instituted and maintained until adequate respiratory muscle function and/or airway protection are assured. Monitor vital signs, cardiac status, respiratory status, and degree of neuromuscular block as ordered. In patients on long-term therapy, monitor for prolonged paralysis and generalized myopathy and reposition patient and provide appropriate skin care, mouth care, and care of patient's eyes every 2 to 3 hours while sedated.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous, as besylate:

Nimbex: 20 mg/10 mL (10 mL) [contains benzyl alcohol]

Generic: 20 mg/10 mL (10 mL); 200 mg/20 mL (20 mL)

Solution, Intravenous, as besylate [preservative free]:

Nimbex: 10 mg/5 mL (5 mL); 200 mg/20 mL (20 mL)

Generic: 2 mg/mL (5 mL); 10 mg/5 mL (5 mL); 10 mg/mL (20 mL); 200 mg/20 mL (20 mL)

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Intravenous, as besylate:

Nimbex: 20 mg/10 mL ([DSC]) [contains benzyl alcohol]

Generic: 10 mg/5 mL (5 mL); 20 mg/10 mL (10 mL)

Anatomic Therapeutic Chemical (ATC) Classification

• M03AC11

Generic Available (US)

Yes

Pricing: US

Solution (Cisatracurium Besylate (PF) Intravenous)

10 mg/5 mL (per mL): $2.88 - $3.61

200 mg/20 mL (per mL): $13.80 - $17.08

Solution (Cisatracurium Besylate Intravenous)

2 mg/mL (per mL): $3.36

10 mg/mL (per mL): $16.23

20 mg/10 mL (per mL): $2.52 - $3.16

Solution (Nimbex Intravenous)

10 mg/5 mL (per mL): $3.76

20 mg/10 mL (per mL): $3.30

200 mg/20 mL (per mL): $17.82

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Blocks neural transmission at the myoneural junction by binding with cholinergic receptor sites

Pharmacodynamics/Kinetics

Onset of action: IV: 2 to 3 minutes

Peak effect: 3 to 5 minutes

Duration: Dose dependent, 35 to 45 minutes after a single 0.1 mg/kg dose; recovery begins in 20 to 35 minutes when anesthesia is balanced; recovery is attained in 90% of patients in 25 to 93 minutes; hypothermia may prolong the duration of action (NCS [Madden 2017])

Distribution: Vdss: 145 mL/kg (21% larger Vdss when receiving inhalational anesthetics)

Protein binding: Not studied due to rapid degradation at physiologic pH

Metabolism: Undergoes rapid nonenzymatic degradation in the bloodstream (Hofmann elimination) to laudanosine and inactive metabolites; laudanosine may cause CNS stimulation (association not established in humans) and has less accumulation with prolonged use than atracurium due to lower requirements for clinical effect

Half-life elimination: 22 to 29 minutes

Excretion: Urine (95%; <10% as unchanged drug); feces (4%)

Clearance: Children: 5.89 mL/kg/minute; Adults: 4.57 mL/kg/minute

Pharmacodynamics/Kinetics: Additional Considerations

Renal function impairment: The times to 90% block were approximately 1 minute slower in patients with ESRD. The half-life values of the metabolites are longer in patients with renal failure and concentrations may be higher after long-term administration.

Hepatic function impairment: The times to maximum block were approximately 1 minute faster in liver transplant patients compared with healthy adults. The half-life values of the metabolites are longer in patients with hepatic disease and concentrations may be higher after long-term administration.

Pediatric: Minor differences in pharmacokinetic/pharmacodynamic parameters in children resulted in a faster time to onset and a shorter duration of neuromuscular block.

Geriatric: The times to maximum block were approximately 1 minute slower in elderly patients.

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

No significant effects or complications reported

Effects on Bleeding

No information available to require special precautions

Related Information

• Neuromuscular-Blocking Agents

Pharmacotherapy Pearls

Cisatracurium is classified as an intermediate-duration neuromuscular-blocking agent. It does not appear to have a cumulative effect on the duration of blockade. Neuromuscular-blocking potency is 3 times that of atracurium; maximum block is up to 2 minutes longer than for equipotent doses of atracurium.

Index Terms

Cisatracurium Besylate

FDA Approval Date

December 15, 1995

References

Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319.[PubMed 11487763]

Baumann, MH, McAlpin BW, Brown K, et al, “A Prospective Randomized Comparison of Train-of-Four Monitoring and clinical Assessment During Continuous ICU Cisatracurium Paralysis,” Chest, 2004, 126(4):1267-73.[PubMed 15486392]

Belmont MR, Lien CA, Quessy S, et al, “The Clinical Neuromuscular Pharmacology of 51W89 in Patients Receiving Nitrous Oxide/Opioid/Barbiturate Anesthesia,” Anesthesiology, 1995, 82(5):1139-45.[PubMed 7741288]

Breslin DS, Jiao K, Habib AS, et al, “Pharmacodynamic Interactions Between Cisatracurium and Rocuronium,” Anesth Analg, 2004, 98(1):107-10.[PubMed 14693597]

Burmester M, Mok Q. Randomised controlled trial comparing cisatracurium and vecuronium infusions in a paediatric intensive care unit. Intensive Care Med. 2005;31(5):686-692.[PubMed 15815895]

Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm[PubMed 6810084]

Greenberg SB and Vender J, “The Use of Neuromuscular Blocking Agents in the ICU: Where Are We Now?” Crit Care Med, 2013, 41(5):1332-44.[PubMed 23591211]

Han TH, Martyn JA. Onset and effectiveness of rocuronium for rapid onset of paralysis in patients with major burns: priming or large bolus. Br J Anaesth. 2009;102(1):55-60.[PubMed 19029093 ]

"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278.[PubMed 9024461]

Konstadt SN, Reich DL, Stanley TE 3d, et al, “A Two Center Comparison of the Cardiovascular Effects of Cisatracurium (Nimbex®) and Vecuronium in Patients With Coronary Artery Disease,” Anesth Analg, 1995, 81(5):1010-4.[PubMed 7486039]

Lagneau F, D’honneur G, Plaud B, et al, “A Comparison of Two Depths of Prolonged Neuromuscular Blockade Induced by Cisatracurium in Mechanically Ventilated Critically Ill Patients,” Intensive Care Med, 2002, 28(12):1735-41.[PubMed 12447516]

Lien CA, Belmont MR, Abalos A, et al, “The Cardiovascular Effects and Histamine-Releasing Properties of 51W89 in Patients Receiving Nitrous Oxide/Opioid/Barbiturate Anesthesia,” Anesthesiology, 1995, 82(5):1131-8.[PubMed 7537945]

Madden LK, Hill M, May TL, et al. The implementation of targeted temperature management: an Evidence-Based Guideline from the Neurocritical Care Society. Neurocrit Care. 2017;27(3):468-487. doi: 10.1007/s12028-017-0469-5.[PubMed 29038971]

Martin LD, Bratton SL, O'Rourke PP. Clinical uses and controversies of neuromuscular blocking agents in infants and children. Crit Care Med. 1999;27(7):1358-1368.[PubMed 10446832]

Miller RD. Miller’s Anesthesia, 7th ed. Philadelphia PA: Churchill Livingstone, 2010.

Murray MJ, Cowen J, DeBlock H, et al, “Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists, American College of Chest Physicians,” Crit Care Med, 2002, 30(1):142-56.[PubMed 11902255]

Murray MJ, DeBlock H, Erstad B, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med. 2016;44(11):2079-2103. doi: 10.1097/CCM.0000000000002027.[PubMed 27755068]

Naguib M, Flood P, McArdle JJ, Brenner HR. Advances in neurobiology of the neuromuscular junction. Implications for the anesthesiologist. Anesthesiology. 2002;96(1):202-31.[PubMed 11753022]

Nimbex (cisatracurium besylate) [prescribing information]. North Chicago, IL: AbbVie Inc; October 2019.

Papazian L, Forel JM, Gacouin A, et al; ACURASYS Study Investigators. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363(12):1107-1116. doi: 10.1056/NEJMoa1005372.[PubMed 20843245]

Playfor S, Jenkins I, Boyles C, et al. Consensus guidelines for sustained neuromuscular blockade in critically ill children. Paediatr Anaesth. 2007;17(9):881-887.[PubMed 17683408]

Prielipp RC, Coursin DB, Scuderi PE, et al, “Comparison of the Infusion Requirements and Recovery Profiles of Vecuronium and Cisatracurium 51W89 in Intensive Care Unit Patients,” Anesth Analg, 1995, 81(1):3-12.[PubMed 7598277]

Siegel MD. Acute respiratory distress syndrome: Supportive care and oxygenation in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed February 15, 2018.

Sorooshian SS, Stafford MA, Eastwood NB, et al, “Pharmacokinetics and Pharmacodynamics of Cisatracurium in Young and Elderly Adult Patients,” Anesthesiology, 1996, 84(5):1083-91.[PubMed 8624002]

Tobias JD. A prospective evaluation of the continuous infusion of cis-atracurium for neuromuscular blockade in the pediatric intensive care unit patient: efficacy and dosage requirements. Am J Ther. 1997;4(9-10):287-290.[PubMed 10423621]

Xu QA, Zhang YP, Trissel LA, et al, “Stability of Cisatracurium Besylate in Vials, Syringes, and Infusion Admixtures,” Am J Health Syst Pharm, 1998, 55(10) :1037-41.[PubMed 9606456 ]

Brand Names: International

Nimbex (AE, AR, AT, AU, BB, BE, BH, BM, BS, BZ, CH, CL, CN, CY, CZ, DE, DK, EC, EG, ES, ET, FI, FR, GB, GR, GT, GY, HK, HN, HU, IE, IL, IQ, IR, IT, JM, JO, KR, KW, LB, LT, LU, LV, LY, MT, MX, MY, NL, NO, OM, PA, PE, PH, PL, PR, PT, QA, RO, RU, SA, SE, SI, SR, SV, SY, TH, TR, TT, TW, YE, ZW); Nimbium (BR, CO)

Last Updated 3/20/20